The Healthtech Times is a weekly newsletter covering healthtech news from Canada and around the globe. Subscribe to H|T using the form at the bottom of this page to ensure you don’t miss out on the most important healthtech news every week!
PocketPills, a healthtech startup offering a full-service digital pharmacy that delivers medication directly to patients, has closed a $7.35 million Series A.
While one-quarter of the total investment in digitization is accounted for by the energy industry, most of the spending will occur across multiple sectors including creative industries, manufacturing, logistics, financial services, life science and agribusiness. Adoption of digital technology will see the fastest growth in agriculture and manufacturing.
The New York-based company, which offers its healthcare services to individuals, health plans and employers, has now raised an additional $45 million to expand its offerings even further.
Precision health startup Q Bio emerges out of stealth with $40M led by Andreessen Horowitz(HITCONSULTANT)
In 75 minutes or less, members are able to get a comprehensive picture of their health and receive a web-based dashboard that they can review from anywhere in the world with their chosen clinicians.
Two Canadian healthtech companies have announced fresh funding to fuel their growth. Here’s the latest on who raised.
London-based health tech startup Second Nature raises $10 million to combat obesity and diabetes(TECH.EU)
London-based Second Nature, the tech-enabled digital health programme designed to combat obesity, has raised $10 million in a funding round led by Beringea.
Mangrove Capital’s Mark Tluszcz on the huge mHealth opportunity and why focusing on UX is key(TECHCRUNCH)
Mangrove Capital Partners’ co-founder and CEO Mark Tluszcz is brimming with enthusiasm for what’s coming down the pipe from health tech startups.
Belgian venture capital firm to finance Canadian biotechs(THEGLOBEANDMAIL)
Up to 20 Quebec startups will receive capital from Theodorus, which opened an office in Montreal.
Finding investors willing to play the long game can be a challenge, a fact that Spartan Bioscience CEO Paul Lem and others in the local biotech space know all too well.